Latest Posts › Private Equity

Share:

Dealmakers prepare to face new uncertainties in 2024

Global M&A activity continued to make slow progress in 2023, with stubbornly high interest rates and stringent financing conditions stifling market confidence. Nearly US$3.2 trillion of M&A deals were announced last year—a...more

Luxury powerhouses turn to M&A amid slowing sales

Declining consumer spending power is driving down revenues and pushing luxury firms to seek new avenues for growth - Slowing economic growth, hampered by stubborn inflation, has inhibited consumer confidence across the...more

US M&A in review: Momentum can only take you so far

M&A started strong in 2022 with robust deal activity and megadeals dominating the landscape that was largely the result of unprecedented spillover from 2021. But then, things took a turn and deals stalled in the second half...more

What’s next for US M&A?

As predicted in our previous M&A report, 2022 has not lived up to the runaway performance of 2021. As activity—still at impressive levels considering everything that has been thrown at the deal market—takes a breather, we...more

US M&A settles back down

Explore the data The headline for the first half of 2022 is that US M&A markets are still remarkably healthy, despite a confluence of headwinds. Without question, 2021 was an exceptional year, fueled by pent-up demand,...more

What's in store for 2022?

Five factors that will shape dealmaking over the coming 12 months - Last year will be a very tough act to follow. M&A values and volumes soared on the back of confident public markets, strong deal financing options and a...more

Surging TMT transactions carry Q2 global M&A to record heights

A brightening macroeconomic outlook and supportive deal environment helped push second-quarter value to a new record Dealmakers hoping for a 2021 rebound in M&A activity have not been disappointed. In Q2 2021, M&A value...more

Healthcare M&A prospers, despite fall in deal activity

The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis - Although pharma, medical and biotech (PMB) M&A deal value for...more

9 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide